Edwards Lifesciences Co. (NYSE:EW) Given Average Rating of “Hold” by Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have received an average recommendation of “Hold” from the twenty-six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $79.95.

Several equities analysts recently weighed in on the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Citigroup increased their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Barclays boosted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th.

Insider Transactions at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at approximately $2,150,791.86. This represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock valued at $2,799,104 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the business. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $29,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $71.38 on Friday. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $72.50 and a two-hundred day simple moving average of $70.33. The stock has a market capitalization of $42.10 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.